We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

135 hedge funds and large institutions have $143M invested in Coherus Oncology in 2024 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 47 increasing their positions, 36 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 36

0% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 24

1% less funds holding

Funds holding: 137 → 135 (-2)

2.16% less ownership

Funds ownership: 74.14% → 71.98% (-2.2%)

28% less capital invested

Capital invested by funds: $198M → $143M (-$54.8M)

32% less call options, than puts

Call options by funds: $219K | Put options by funds: $321K

Holders
135
Holders Change
-2
Holders Change %
-1.46%
% of All Funds
1.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
47
Reduced
36
Closed
24
Calls
$219K
Puts
$321K
Net Calls
-$102K
Net Calls Change
-$84K

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$2.11M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$2.01M
3
AQR Capital Management
AQR Capital Management
Connecticut
+$1.45M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.05M
5
BlackRock
BlackRock
New York
+$1.05M

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$4.33M
2
Temasek Holdings
Temasek Holdings
Singapore
-$3.14M
3
Morgan Stanley
Morgan Stanley
New York
-$2.23M
4
Millennium Management
Millennium Management
New York
-$1.29M
5
Two Sigma Investments
Two Sigma Investments
New York
-$1.26M
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
26
Clearline Capital
New York
$1.36M – – –
AQR Capital Management
27
AQR Capital Management
Connecticut
$1.25M +$1.45M +719,999 New
BGIM
28
Brandywine Global Investment Management
Pennsylvania
$1.21M +$289K +143,700 +26%
Lazard Asset Management
29
Lazard Asset Management
New York
$1.09M +$489K +243,047 +63%
Millennium Management
30
Millennium Management
New York
$1.07M -$1.29M -641,335 -51%
Norges Bank
31
Norges Bank
Norway
$850K +$989K +491,500 New
Citigroup
32
Citigroup
New York
$804K -$105K -52,261 -10%
Marshall Wace
33
Marshall Wace
United Kingdom
$727K +$541K +268,763 +177%
BNP Paribas Financial Markets
34
BNP Paribas Financial Markets
France
$711K +$131K +64,943 +19%
Renaissance Technologies
35
Renaissance Technologies
New York
$683K +$488K +242,500 +159%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$673K +$161K +80,222 +26%
Wellington Management Group
37
Wellington Management Group
Massachusetts
$640K +$57.4K +28,500 +8%
SEI Investments
38
SEI Investments
Pennsylvania
$615K -$3.19K -1,586 -0.4%
WP
39
Woodline Partners
California
$558K -$428K -212,759 -40%
BCC
40
Bridge City Capital
Oregon
$547K +$1.26K +625 +0.2%
Bank of America
41
Bank of America
North Carolina
$476K -$4.33M -2,152,130 -89%
XT
42
XTX Topco
Cayman Islands
$470K +$411K +204,391 +305%
BC
43
Birchview Capital
Vermont
$467K – – –
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
$430K -$287K -142,682 -36%
BCM
45
Bridgeway Capital Management
Texas
$420K +$489K +243,000 New
TWP
46
Tyche Wealth Partners
Texas
$374K – – –
Two Sigma Advisers
47
Two Sigma Advisers
New York
$366K +$9.06K +4,500 +2%
Los Angeles Capital Management
48
Los Angeles Capital Management
California
$362K +$26.7K +13,250 +7%
Jane Street
49
Jane Street
New York
$361K -$308K -153,089 -42%
JFG
50
Jefferies Financial Group
New York
$340K – – –
1
2
3 4 5

CHRS Hedge Fund Activity: Q2 2024 in Review

135 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2024, worth a combined $143M — down 28% from $198M a quarter earlier.

Fund positioning in CHRS was balanced in Q2 2024: 24 funds opened new positions, 24 closed out, 47 added to existing stakes and 36 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $2.11M. The largest seller was Bank of America, cutting an estimated $4.33M.

  • 135 institutional investors held Coherus Oncology (CHRS) as of Q2 2024, down from 137 in Q1 2024.
  • Funds reported $143M of Coherus Oncology stock for Q2 2024, down 28% quarter-over-quarter.
  • 24 funds opened new Coherus Oncology positions in Q2 2024 and 24 closed out, a net change of 0 holders.
  • The largest Coherus Oncology buyer in Q2 2024 was Tang Capital Management, an estimated $2.11M added.
  • The largest Coherus Oncology seller in Q2 2024 was Bank of America, an estimated $4.33M sold.

Based on aggregated 13F filings for Q2 2024.